Billions of Dollars on the Line for Celgene With These 3 Small Biotechs – Madison.com
Madison.com |
Billions of Dollars on the Line for Celgene With These 3 Small Biotechs
Madison.com In 2015, Celgene forged another relationship with a small biotech specializing in treating cancer via chimeric antigen receptor T–cell (CAR-T) therapies — Juno Therapeutics. The deal involved collaboration on several of Juno's immunotherapy candidates. |
